ERBB2 and neoplasm: The trastuzumab component of T-DM1 targets the agent to HER2-expressing tumor cells, within which it is internalized and lysine-Nε-4 -MCC-DM1 is released intracellularly, resulting in microtubule instability and apoptosis [6,7].